TGFB1 and pulmonary arterial hypertension: The power of leveraging human genetic data in drug target identification has received an important validation in the recent demonstration of surprisingly large functional treatment effect sizes in diverse populations of group 1 PAH patients already established on dual and triple therapy and targeting the TGF-β superfamily with an activin receptor Fc fusion protein (Sotatercept) [6].